These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7330975)

  • 21. Unexpected reaction of anti-H-2d serum with thymic lymphoma cells derived from transgenic B6-H-2b TCR anti-HY/Db mice.
    Matuszyk J; Zioło E; Kobzdej M; Strzadala L
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):103-7. PubMed ID: 8915513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specificity of homograft rejection in vivo, assessed by inoculation of artificially mixed compatible and imcompatible tumor cells.
    Klein E; Klein G
    Cell Immunol; 1972 Sep; 5(1):201-8. PubMed ID: 5078988
    [No Abstract]   [Full Text] [Related]  

  • 23. Antigenic modulation as a mechanism for tumor escape from immune destruction: identification of modulation-positive and modulation-negative mouse lymphomas with xenoantisera to murine leukemia virus gp70.
    Stackpole CW; Cremona P; Leonard C; Stremmel P
    J Immunol; 1980 Oct; 125(4):1715-23. PubMed ID: 6251136
    [No Abstract]   [Full Text] [Related]  

  • 24. DBA/2-like minor histocompatibility antigens on a BALB/c lymphoma. A BALB/c anti-DBA/2 serum which lyses the tumor and blocks BALB/c anti-tumor and anti-DBA/2 effectors.
    Ballinari D; Grazioli L; Sensi ML; Borrello MG; Parmiani G
    Int J Cancer; 1985 Nov; 36(5):617-22. PubMed ID: 3877002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lectin-induced nonlethal adhesions between cytolytic T lymphocytes and antigenically unrecognizable tumor cells and nonspecific "triggering" of cytolysis.
    Parker WL; Martz E
    J Immunol; 1980 Jan; 124(1):25-35. PubMed ID: 6765968
    [No Abstract]   [Full Text] [Related]  

  • 26. Source of tumor cells influences their immune recognition by H-2-matched mice.
    Forni G; Varesio L; Giovarelli M; Landolfo S
    Transplantation; 1979 Jun; 27(6):433-5. PubMed ID: 462530
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysis of a defect in the H-2 genes of SV40 transformed C3H fibroblasts that do not express H-2Kk.
    Rogers MJ; Gooding LR; Margulies DH; Evans GA
    J Immunol; 1983 May; 130(5):2418-22. PubMed ID: 6300246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endotoxin-stimulated immune response to modified lymphoma cells.
    Prager MD; Ludden CM; Mandy WJ; Allison JP; Kitto GB
    J Natl Cancer Inst; 1975 Mar; 54(3):773-5. PubMed ID: 1168264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of allosensitized memory lymphocytes into secondary cytotoxic T lymphocytes by third-party stimulator cells: genetic mapping of the stimulating antigens.
    Fan J; Bonavida B
    Transplant Proc; 1981 Dec; 13(4):1897-900. PubMed ID: 7330974
    [No Abstract]   [Full Text] [Related]  

  • 30. Variation in expression of H-2 histocompatibility antigens on tumor cells.
    Imamura M; Martin WJ
    Transplant Proc; 1980 Mar; 12(1):77-9. PubMed ID: 6445108
    [No Abstract]   [Full Text] [Related]  

  • 31. Characterization of a lymphoma cell variant selectively resistant to natural killer cells.
    Durdik JM; Beck BN; Clark EA; Henney CS
    J Immunol; 1980 Aug; 125(2):683-8. PubMed ID: 6771330
    [No Abstract]   [Full Text] [Related]  

  • 32. Non-H-2 restriction specificity of tumor-regressor mouse sera with regard to their activity to inhibit tumor cell transplantation.
    Egawa K; Kiyohara T; Tanino T
    Jpn J Exp Med; 1982 Oct; 52(5):255-60. PubMed ID: 7169670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of feeding syngeneic and allogeneic tissues on growth of an allotransplantable tumor.
    Breyere EJ; Heath JR
    Transplant Proc; 1977 Jun; 9(2):1459-63. PubMed ID: 878012
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of tumor and histocompatibility antigens in sera of lymphoma-bearing mice.
    Fujimoto S; Chen CH; Sabbadini E; Sehon AH
    J Immunol; 1973 Oct; 111(4):1093-100. PubMed ID: 4728678
    [No Abstract]   [Full Text] [Related]  

  • 35. Macrophages/monocytes require cell-to-cell contact in order to regulate the growth of a murine lymphoma cell line.
    Hewlett G; Opitz HG; Flad HD; Schlumberger HD
    J Immunol; 1979 Nov; 123(5):2265-9. PubMed ID: 489982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. F1 hybrid resistance to murine plasmacytoma MOPC-70A: hybrid resistance to MOPC-70A controlled by a locus linked to H-2.
    Kaneko Y; Natsuume-Sakai S; Moriwaki K; Migita S
    J Immunol; 1980 Nov; 125(5):2031-8. PubMed ID: 7430619
    [No Abstract]   [Full Text] [Related]  

  • 37. [Appearance of new transplantation antigens in tumor cells treated with RNA].
    Nikolin VP; Il'nitskaia SI; Gruntenko EV; Tomsons VP
    Eksp Onkol; 1984; 6(1):42-7. PubMed ID: 6209090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunogenic and tumorigenic properties of a murine lymphoma that expresses foreign alloantigens: role of helper factor(s) in generating a cytotoxic response in vitro.
    Scott JW; Finke JH
    Transplant Proc; 1981 Dec; 13(4):1867-73. PubMed ID: 6800082
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of immune responses in mice after transfusions from single or multiple H-2 donors.
    Joseph S; Singal DP; Ludwin D
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1168. PubMed ID: 2705218
    [No Abstract]   [Full Text] [Related]  

  • 40. MHC-coded unique alloantigens and antitumor immunity.
    Martin WJ
    Transplant Proc; 1981 Dec; 13(4):1837-40. PubMed ID: 7036480
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.